AlkermesALKS
ALKS
About: Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Employees: 1,800
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
107% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 30
16% more capital invested
Capital invested by funds: $4.81B [Q4 2024] → $5.59B (+$779M) [Q1 2025]
8% more funds holding
Funds holding: 340 [Q4 2024] → 366 (+26) [Q1 2025]
0.74% more ownership
Funds ownership: 103.35% [Q4 2024] → 104.09% (+0.74%) [Q1 2025]
3% less repeat investments, than reductions
Existing positions increased: 126 | Existing positions reduced: 130
14% less funds holding in top 10
Funds holding in top 10: 7 [Q4 2024] → 6 (-1) [Q1 2025]
46% less call options, than puts
Call options by funds: $7.68M | Put options by funds: $14.3M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$33
11%
upside
Avg. target
$42
41%
upside
High target
$52
74%
upside
5 analyst ratings
3 positive
60%
2 neutral
40%
0 negative
0%
Needham Ami Fadia | 51%upside $45 | Buy Initiated | 28 May 2025 |
RBC Capital Leonid Timashev | 34%upside $40 | Sector Perform Maintained | 2 May 2025 |
Baird Joel Beatty | 37%upside $41 | Outperform Maintained | 2 May 2025 |
UBS Ashwani Verma | 11%upside $33 | Neutral Maintained | 28 Apr 2025 |
Deutsche Bank David Hoang | 74%upside $52 | Buy Maintained | 27 Mar 2025 |
Financial journalist opinion
Neutral
PRNewsWire
1 week ago
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
DUBLIN , June 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 10:00 a.m. EDT (3:00 p.m.
Neutral
PRNewsWire
1 week ago
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences
– Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles – DUBLIN , June 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring, including presentations largely related to its psychiatry products LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil). Several of these meetings coincided with Mental Health Awareness Month in May, an important moment to raise awareness about mental health conditions, support the millions of people living with these complex diseases, and acknowledge the critical work of healthcare providers.
Negative
Zacks Investment Research
1 month ago
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates
ALKS' earnings and revenues lag first-quarter 2025 estimates. Sales of proprietary products surpass management's expectations.
Positive
Seeking Alpha
1 month ago
Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible
The company's drug LYBALVI, approved for adults with Schizophrenia and bipolar I disorder, shows potential for label expansion to include pediatric patients to potentially boost revenue growth. The ongoing phase 3 ENLIGHTEN-Youth trial aims to evaluate LYBALVI's efficacy and safety in pediatric patients, with a primary completion date of September 2026. Long-term data indicates minimal weight gain with LYBALVI, addressing a major concern with mental health medications and supporting its market potential.
Neutral
Zacks Investment Research
1 month ago
Here's What Key Metrics Tell Us About Alkermes (ALKS) Q1 Earnings
While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Neutral
Seeking Alpha
1 month ago
Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS ) Q1 2025 Results Conference Call May 1, 2025 8:00 AM ET Company Participants Sandy Coombs - Senior Vice President of Corporate Affairs and Investor Relations Richard Pops - Chairman and Chief Executive Officer Todd Nichols - Senior Vice President and Chief Commercial Officer Blair Jackson - Executive Vice President and Chief Operating Officer Craig Hopkinson - Chief Medical Officer Conference Call Participants Joseph Thome - TD Cowen Charles Duncan - Cantor Fitzgerald Umer Raffat - Evercore ISI David Amsellem - Piper Sandler Marc Goodman - Leerink Partners Jason Gerberry - Bank of America Leonid Timashev - RBC Capital Markets Uy Ear - Mizuho Securities Joel Beatty - Baird David Hoang - Deutsche Bank Douglas Tsao - H.C. Wainwright Operator Greetings, and welcome to Alkermes' First Quarter 2025 Financial Results Conference Call.
Negative
Zacks Investment Research
1 month ago
Alkermes (ALKS) Misses Q1 Earnings and Revenue Estimates
Alkermes (ALKS) came out with quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.44 per share a year ago.
Neutral
PRNewsWire
1 month ago
Alkermes plc Reports First Quarter 2025 Financial Results
— First Quarter Revenues of $306.5 Million — — GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 — — Company Reiterates 2025 Financial Expectations — DUBLIN , May 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2025. "Our first quarter financial performance provides a solid foundation to deliver on our financial guidance for the year.
Neutral
PRNewsWire
1 month ago
New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD)
– Survey Respondents Reported That AUD Diagnosis and Decision to Seek Treatment Were Driven by Negative Consequences of Drinking – – Respondents Cited the Influence of Their Healthcare Providers and the Positive Impact of Treatment on Their Lives – DUBLIN , April 30, 2025 /PRNewswire/ -- A new online survey conducted by The Harris Poll on behalf of Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), sought to understand utilization of and experiences with treatment among 300 adults between ages 21-64 who self-identify as having been diagnosed with alcohol use disorder (AUD) by a healthcare provider. The survey showed that the path to AUD diagnosis can be challenging and often driven by negative consequences, but treatment may positively impact people living with AUD.
Negative
Zacks Investment Research
1 month ago
Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charts implemented using Lightweight Charts™